Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Polycystic Ovary Syndrome 2Pituitary Neoplasms 2Urinary Bladder Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Sezary Syndrome 1Sarcoma 1Prostatic Neoplasms 1Pituitary ACTH Hypersecretion 1Pancreatic Neoplasms 1Obesity 1Mycosis Fungoides 1Melanoma 1Lymphoma, T-Cell, Cutaneous 1Liposarcoma 1Diabetes Mellitus, Type 2 1Central Nervous System Neoplasms 1Carcinoma, Hepatocellular 1Breast Neoplasms 1Adenocarcinoma Of Esophagus 1

Interventions

Radiotherapy 9Doxorubicin 7pazopanib 5palbociclib 4Trabectedin 4Gemcitabine 4ribociclib 3pembrolizumab 3eribulin 3Magnetic Resonance Spectroscopy 3selinexor 2liposomal doxorubicin 2avelumab 2abemaciclib 2Sunitinib 2Radiation Dose Hypofractionation 2Radiation 2Immunoglobulin G 2Ifosfamide 2Docetaxel 23-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione 2zimberelimab 1temsirolimus 1sotigalimab 1sodium thiosulfate 1sitravatinib 1silmitasertib 1sargramostim 1romidepsin 1regorafenib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Liposarcoma × Rosiglitazone × Clear all
NCT00004180 2023-06-26

Rosiglitazone in Treating Patients With Liposarcoma

Dana-Farber Cancer Institute

Phase 2 Completed
32 enrolled
Sarcoma

Liposarcoma, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡